Abstract 2568
Background
Pathological complete response (pCR) is an established surrogate marker for survival in breast cancer (BC) patients treated with neoadjuvant chemotherapy. Prediction of pCR based on clinical information available at biopsy, particularly the biomarkers estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 expression, might assist in the identification of patients who benefit of preoperative chemotherapy. Although biomarker assessment is mostly reported as the percentage of positively stained cells with values from 0 to 100%, cut-off points are used to classify patients into groups. Aim of this study was to examine established cut-off points and to develop a prediction tool estimating a patient’s pCR likelihood obtained from clinical predictors and these biomarkers as assessed during clinical routine or categorically with established or newfound thresholds.
Methods
This study included all HER2-negative BC patients from one German institution treated with neoadjuvant chemotherapy from 2002 to 2017, having complete observations (N = 829). Various logistic regression models for predicting pCR which differ from each other by the usage of the biomarkers were set-up: (M1) continuous biomarkers from 0 to 100% as assessed during clinical routine, (M2) categorical (positive/negative) biomarkers with established thresholds, (M3) categorical biomarkers with newfound thresholds. Prediction accuracy (e.g., AUC) was assessed using cross-validation.
Results
A total of 163 (19.7%) patients achieved a pCR. The optimal cut-off points for ER, PgR and Ki-67 were 30%, 10% and 35%, respectively. The prediction model M1 with continuous biomarkers was more precise (cross-validated AUC, 0.863) than the prediction models M2 and M3 (both 0.854). The most accurate model M1 had a sensitivity of 0.80 at a specificity of 0.78. Beside these biomarkers, a patient’s likelihood of achieving a pCR depended on age at diagnosis, clinical tumor stage and grading.
Conclusions
Using biomarkers as continuous variables yielded more precise predictions than when used categorically. Therapy decisions should base on predicted pCR probabilities obtained from multivariable prediction models rather than single biomarker values.
Clinical trial identification
Legal entity responsible for the study
Erlangen University Hospital, Erlangen.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
A. Hartmann: Personal fees: AstraZeneca, BMS, MSD; Grants: Biontech, Nanostring; Personal fees and non-financial support: Roche, Sysmex; Grants: Janssen, Cepheid outside the submitted work. P.A. Fasching: Grants and personal fees: Novartis; Personal fees: Pfizer, Roche, Teva, Celgene; Grants: Biontech, outside the submitted work. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract